The Brod Group (TBG), a science-based health outcome research group is developing a study on children’s and parent’s life experience with achondroplasia. This study is a pilot test for a survey and TBG is searching for participants for individual telephone interviews.

ACHieve is the observational study for achondroplasia sponsored by Ascendis Pharma and is now recruiting.

Ascendis Pharma A/S announced on the 28th February 2019, on the rare disease day that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation (ODD) to TransCon CNP.

The Sunnaas Rehabilitation Hospital is conducting an observational study on the prevalence of medical complications in adults with achondroplasia and their impact on daily activities entitled "The Norwegian Adult Achondroplasia Study".

Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia, conducted by Therachon, is an observational study to investigate natural history of achondroplasia. It is currently recruiting for a number of countries.

LIAISE is the Lifetime Impact of Achondroplasia Study in Europe. It will gather information on the clinical and medical interventions of people with achondroplasia, individuals' and caregivers' quality of life and the impact of this condition on education, employment and social life.